Nova Biomedical Advances Integrated Cell Line Development Workflows: NanoCellect products are now part of Nova Biomedical

Positive

AI Analysis

Summary

Nova Biomedical announced an asset transaction involving NanoCellect's microfluidic cell sorting technology, expanding Nova's capabilities in cell line development. The acquisition strengthens Nova's position in cell sorting and bioprocessing workflows.

Importance:5/10

Sentiment:

0.60

M&Acell line developmentmicrofluidic technologyasset acquisition

Related Companies

$INBP

Read the original article

Published by PR Newswire Biotech on July 24, 2026 1:46 PM

Read Original